Compare MIGI & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MIGI | GLMD |
|---|---|---|
| Founded | 2012 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 4.4M |
| IPO Year | 2013 | 2013 |
| Metric | MIGI | GLMD |
|---|---|---|
| Price | $2.69 | $0.62 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 46.6K | ★ 52.7K |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.90 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,571,720.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $0.50 |
| 52 Week High | $15.80 | $3.50 |
| Indicator | MIGI | GLMD |
|---|---|---|
| Relative Strength Index (RSI) | 36.62 | 45.14 |
| Support Level | $0.39 | $0.50 |
| Resistance Level | $3.50 | $0.69 |
| Average True Range (ATR) | 0.25 | 0.05 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 15.12 | 59.47 |
Mawson Infrastructure Group Inc is a digital infrastructure provider with diversified operations across Cryptocurrency Mining and Digital Asset Management. Its mission is to build a bridge between the rapidly emerging digital asset industry and traditional capital markets, with a focus on shareholder returns. The Company has three primary businesses: digital currency or Bitcoin self-mining, customer co-location and related services, and energy markets. It operates in a single segment surrounding its digital currency mining operation.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.